These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 30933478)
1. ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer. Xin X; Lin F; Wang Q; Yin L; Mahato RI ACS Appl Mater Interfaces; 2019 Apr; 11(16):14647-14659. PubMed ID: 30933478 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice. Kumar V; Mundra V; Peng Y; Wang Y; Tan C; Mahato RI Theranostics; 2018; 8(15):4033-4049. PubMed ID: 30128034 [No Abstract] [Full Text] [Related]
3. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53. Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681 [TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo. Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694 [TBL] [Abstract][Full Text] [Related]
9. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms. Nguyen T; Parker R; Hawkins E; Holkova B; Yazbeck V; Kolluri A; Kmieciak M; Rahmani M; Grant S Oncotarget; 2017 May; 8(19):31478-31493. PubMed ID: 28416758 [TBL] [Abstract][Full Text] [Related]
10. Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancer. Kumar V; Mondal G; Slavik P; Rachagani S; Batra SK; Mahato RI Mol Pharm; 2015 Apr; 12(4):1289-98. PubMed ID: 25679326 [TBL] [Abstract][Full Text] [Related]
11. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992 [TBL] [Abstract][Full Text] [Related]
12. Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor. Van den Bossche J; Lardon F; Deschoolmeester V; De Pauw I; Vermorken JB; Specenier P; Pauwels P; Peeters M; Wouters A Med Res Rev; 2016 Jul; 36(4):749-86. PubMed ID: 27140825 [TBL] [Abstract][Full Text] [Related]
13. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines. Münch C; Dragoi D; Frey AV; Thurig K; Lübbert M; Wäsch R; Bogatyreva L; Hauschke D; Lassmann S; Werner M; May AM Leuk Res; 2015 Apr; 39(4):462-70. PubMed ID: 25697066 [TBL] [Abstract][Full Text] [Related]
15. Tuned Density of Anti-Tissue Factor Antibody Fragment onto siRNA-Loaded Polyion Complex Micelles for Optimizing Targetability into Pancreatic Cancer Cells. Min HS; Kim HJ; Ahn J; Naito M; Hayashi K; Toh K; Kim BS; Matsumura Y; Kwon IC; Miyata K; Kataoka K Biomacromolecules; 2018 Jun; 19(6):2320-2329. PubMed ID: 29767505 [TBL] [Abstract][Full Text] [Related]
16. Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer. Saatci Ö; Borgoni S; Akbulut Ö; Durmuş S; Raza U; Eyüpoğlu E; Alkan C; Akyol A; Kütük Ö; Wiemann S; Şahin Ö Oncogene; 2018 Apr; 37(17):2251-2269. PubMed ID: 29391599 [TBL] [Abstract][Full Text] [Related]
17. BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells. Chen E; Pei R J Int Med Res; 2020 May; 48(5):300060520926093. PubMed ID: 32468878 [TBL] [Abstract][Full Text] [Related]
18. Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells. Sydor S; Jafoui S; Wingerter L; Swoboda S; Mertens JC; Gerken G; Canbay A; Paul A; Fingas CD World J Gastroenterol; 2017 Jun; 23(22):4007-4015. PubMed ID: 28652654 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo. Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of Suicidal Erythrocyte Death by Volasertib. Al Mamun Bhuyan A; Ashiqul Haque AKM; Sahu I; Cao H; Kormann MSD; Lang F Cell Physiol Biochem; 2017; 43(4):1472-1486. PubMed ID: 29035889 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]